Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07579221RecruitingPhase 1/Phase 2
Navlimetostat and Pumitamig for Advanced Lung Cancer
This study tests a combination of two experimental drugs (navlimetostat and pumitamig) for advanced non-small cell lung cancer in patients whose tumors have a specific genetic change called MTAP loss. The drugs are designed to attack cancer cells in a new way and may help patients whose cancer has stopped responding to previous treatments.
Houston, TexasAges 18 years+ - NCT06734533Recruiting
Anlotinib combo for HR+ breast cancer that has spread
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Changsha, HunanAges 18–75 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07542496Recruiting
Real-world study of breast cancer treatment with pertuzumab biosimilar
This study observes how a biosimilar version of pertuzumab (a targeted breast cancer drug) works in real-world patients. Researchers will track outcomes in patients receiving this drug either before surgery or as a first treatment for advanced breast cancer.
AlgiersAges 19 years+ - NCT07539155RecruitingPhase 1/Phase 2
MMR Vaccine Injection for Advanced Pancreatic Cancer
This trial tests whether injecting an MMR (measles, mumps, rubella) vaccine directly into a pancreatic tumor can help your immune system fight the cancer. You're eligible if your pancreatic cancer cannot be surgically removed after standard chemotherapy and radiation treatment.
Little Rock, ArkansasAges 18 years+ - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07483658Recruiting
Salvage pelvic radiotherapy: 20 vs 25 sessions for recurring prostate cancer
This trial compares two schedules of pelvic radiotherapy for men whose prostate cancer has returned after surgery. Both schedules aim to control the cancer with fewer visits for one of them.
Gatineau, QuebecAges 18 years+ - NCT07477626RecruitingPhase 3
Radiation therapy after prostate surgery for advanced prostate cancer
This study tests whether radiation therapy to the pelvis after prostate removal helps men whose cancer was found in nearby lymph nodes. The goal is to prevent cancer from coming back and improve survival.
Dongguan, GuangdongAges 18 years+ - NCT06758557RecruitingPhase 1/Phase 2
HB0025 for advanced solid tumors
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
Baoding, HebeiAges 18–75 - NCT06793813RecruitingPhase 2
Study of cadonilimab for advanced lung cancer
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07425002Recruiting
Precision Oncology Study in Breast Cancer (PRISM)
This study looks at tumor tissue from people with breast cancer, including those with brain metastases. It aims to learn more about the genetic changes in the cancer to help guide future treatments.
Dublin, LeinsterAges 18 years+ - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT07389512Recruiting
Pharmaceutical management in targeted radionuclide therapy study
This study is for adults who are getting targeted radionuclide therapy and have a pharmacist involved in managing their medicines. It looks at how the medication is handled to improve treatment safety and effectiveness.
BronAges 18 years+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.